http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20130056885-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ff0114fc81999253226dd38509d1068 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56 |
| filingDate | 2010-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb0fd6c4c43d9aa0fb7e7a8c7643b873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a575d83da7a5a1d678d5f5d97cfcbce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7271f31f2f498d2501c674d5014dc8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0471a2104965df2eea857da2e2aee9a9 |
| publicationDate | 2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20130056885-A |
| titleOfInvention | Stable New Conjugates of Interferon Alpha and Polyethylene Glycol Expressed as Single Position Isomers |
| abstract | The present invention relates to the pharmaceutical industry and pharmaceuticals, in particular novel PEG-interferon derivatives and novel polyethylene glycols and interferons represented by formula (I), which have interferon alpha activity, reduced immunogenicity, prolonged biological effects and improved pharmacokinetic parameters. Relates to the discovery of functionally active, high stability conjugates, wherein n is an integer from 227 to 10000 resulting in a molecular weight of PEG of about 10000 to 40000 Da; m is an integer of ≧ 4; IFN is an IFN-α Active natural or recombinant polypeptide.] The invention also provides for the treatment of drugs, viral infections and cancers, as well as diseases associated with primary or secondary immunodeficiency, containing the claimed conjugate represented by formula (I). A pharmaceutical composition comprising a therapeutically acceptable excipient and a PEG-IFN conjugate suitable for the present invention. Preventing and / or treating a disease associated with primary or secondary immunodeficiency, including the use of formula (I) for use in drugs with immunomodulatory activity, the administration of a therapeutically effective amount of a conjugate represented by formula (I) To a container having said pharmaceutical composition: (I) |
| priorityDate | 2010-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.